Isordil

Prodotti simili

Ecosprin

Prezzo da €16.22

Vedi

Propranolol

Prezzo da €39.28

Vedi

Toprol XL

Prezzo da €19.64

Vedi

Prinivil

Prezzo da €34.16

Vedi

Diltiazem HCL

Prezzo da €44.40

Vedi

Accupril

Prezzo da €58.07

Vedi

Product Description

Isordil, known generically as isosorbide dinitrate, is an organic nitrate vasodilator primarily used in the management and prevention of angina pectoris (chest pain) due to coronary artery disease. It is available in various formulations, including sublingual tablets, chewable tablets, and oral extended-release formulations. Its fundamental action is to reduce cardiac workload and myocardial oxygen demand by causing venous and arterial dilation, thereby providing relief from and prophylaxis against anginal attacks. This monograph provides a comprehensive, evidence-based review of Isordil for healthcare professionals and informed patients.

1. Introduction: What is Isordil? Its Role in Modern Cardiology

Isordil is classified as a long-acting organic nitrate. For decades, it has served as a fundamental therapeutic agent in the pharmacologic arsenal against ischemic heart disease. While newer antianginal classes like beta-blockers and calcium channel blockers have expanded treatment options, Isordil retains a critical, evidence-based role, particularly for acute symptom relief and in combination regimens for chronic stable angina. Its significance lies in its rapid onset of action (especially in sublingual form) and its predictable hemodynamic effects. For the patient or clinician searching “what is Isordil used for,” the primary answer remains: the prevention and treatment of angina pectoris by improving the balance between myocardial oxygen supply and demand.

2. Key Components and Pharmacokinetics of Isordil

The active pharmaceutical ingredient is isosorbide dinitrate. Its efficacy is intrinsically linked to its pharmacokinetic profile and the specific formulation prescribed, which dictates the onset and duration of action.

• Composition: The core molecule is isosorbide dinitrate, an organic nitrate ester.
• Release Forms & Bioavailability:
  • Sublingual Tablets (2.5 mg, 5 mg): Designed for rapid dissolution under the tongue, bypassing first-pass hepatic metabolism. This results in a rapid onset of action (2-5 minutes), making it ideal for aborting an acute anginal attack or for prophylaxis immediately prior to known exertion. The duration of effect is relatively short (1-2 hours).
  • Chewable Tablets (5 mg, 10 mg): Also provides a relatively quick onset as the medication is absorbed through the buccal mucosa.
  • Oral Extended-Release Tablets/Swallowable Tablets (e.g., 20 mg, 30 mg, 40 mg): These are intended for chronic prophylactic therapy. They undergo significant first-pass metabolism in the liver to active metabolites (primarily isosorbide-5-mononitrate). Onset is slower (~1 hour), with a longer duration intended to provide background prophylaxis. It is crucial to adhere to the prescribed schedule, typically 2-3 times daily with a mandatory nitrate-free interval (discussed in Section 5) to prevent tolerance.

The choice of formulation is a direct clinical decision based on whether the goal is immediate relief or long-term prevention.

3. Mechanism of Action of Isordil: Scientific Substantiation

Understanding how Isordil works requires a dive into vascular biochemistry. Isosorbide dinitrate is a prodrug. It is metabolized within vascular smooth muscle cells to release nitric oxide (NO). Nitric oxide is a potent endogenous vasodilator identical to the endothelium-derived relaxing factor (EDRF).

• Primary Pathway: NO activates the enzyme guanylyl cyclase, leading to an increase in intracellular cyclic guanosine monophosphate (cGMP). Elevated cGMP causes dephosphorylation of myosin light chains, resulting in smooth muscle relaxation.
• Hemodynamic Effects:
  1. Venodilation (Primary Effect): Dilation of the systemic veins (venules) increases venous capacitance, leading to pooling of blood in the periphery. This reduces venous return to the heart (preload), which in turn decreases ventricular wall tension and myocardial oxygen consumption.
  2. Arteriolar Dilation: At higher doses, Isordil also causes dilation of systemic arterioles, reducing systemic vascular resistance and arterial pressure (afterload). This further decreases the heart’s workload.
  3. Coronary Vasodilation: Dilation of epicardial coronary arteries and collateral vessels can improve blood flow to ischemic regions of the myocardium.

In simple terms, Isordil works primarily by reducing the heart’s demand for oxygen (by making its pumping job easier) and secondarily by potentially improving oxygen supply to heart muscle.

4. Indications for Use: What is Isordil Effective For?

The use of Isordil is supported by extensive clinical guidelines and decades of practice.

Isordil for Acute Angina Relief

The sublingual or chewable form is a standard “as-needed” medication for acute episodes of angina pectoris. Patients are instructed to use it at the first sign of chest discomfort.

Isordil for Chronic Stable Angina Prophylaxis

Oral extended-release formulations are used on a scheduled basis to reduce the frequency and severity of anginal episodes. It is often used in combination with beta-blockers or calcium channel blockers for synergistic effect.

Isordil in Heart Failure with Reduced Ejection Fraction (HFrEF)

While not a first-line agent, nitrates like isosorbide dinitrate, especially when combined with hydralazine, have a Class I recommendation in guidelines for treating HFrEF in self-identified Black patients. This combination, based on the landmark A-HeFT trial, improves mortality and hospitalization rates in this population.

Isordil for Vasospastic (Prinzmetal’s) Angina

Due to its direct coronary vasodilatory effect, it can be effective in preventing coronary artery spasm.

5. Instructions for Use: Dosage and Course of Administration

Dosing is highly individualized and formulation-dependent. The following table provides general guidelines.

Administration Notes: Sublingual tablets should not be swallowed. They must dissolve under the tongue without eating or drinking during dissolution. Patients should sit down when taking the first dose due to the risk of orthostatic hypotension.

6. Contraindications and Drug Interactions with Isordil

Contraindications:

• Hypersensitivity to nitrates or any component.
• Concomitant use with phosphodiesterase-5 (PDE-5) inhibitors (e.g., sildenafil, tadalafil, vardenafil). This combination can cause profound, life-threatening hypotension.
• Severe anemia.
• Closed-angle glaucoma (relative contraindication; risk is often overstated but requires caution).
• Cardiogenic shock or severe hypotension.

Significant Drug Interactions:

• PDE-5 Inhibitors (Absolute Contraindication): As above. A minimum 24-hour (for sildenafil/vardenafil) to 48-hour (for tadalafil) washout period is required.
• Other Antihypertensives, Diuretics, Beta-Blockers, Calcium Channel Blockers: Additive hypotensive effects. Blood pressure requires careful monitoring.
• Alcohol: Potentiates vasodilation and hypotension.
• Heparin: There is some evidence nitrates may reduce heparin’s anticoagulant effect; monitor PTT.

Use in Special Populations:

• Pregnancy/Lactation: Category C. Use only if potential benefit justifies potential fetal risk. Should be used with caution during breastfeeding.
• Geriatric Patients: Increased sensitivity to hypotensive effects; initiate at low end of dosing range.

7. Clinical Studies and Evidence Base for Isordil

The clinical studies supporting organic nitrates are foundational. While older, they established the efficacy paradigm.

• Acute and Chronic Angina: Numerous controlled trials have consistently demonstrated the superiority of sublingual nitrates over placebo in terminating acute angina attacks and increasing exercise tolerance in stable angina. The ACIP study (Asymptomatic Cardiac Ischemia Pilot) helped refine the understanding of dosing schedules to mitigate tolerance.
• Heart Failure - V-HeFT I & II and A-HeFT: The Vasodilator-Heart Failure Trials established isosorbide dinitrate + hydralazine as a mortality-reducing regimen. The African-American Heart Failure Trial (A-HeFT) prospectively confirmed a 43% reduction in mortality and 33% reduction in first hospitalization in Black patients with HFrEF, leading to its specific guideline recommendation.
• Tolerance Phenomenon: Robust scientific evidence confirms that continuous nitrate exposure leads to tolerance within 24 hours, blunting therapeutic effect. The requirement for a nitrate-free interval is a direct result of this body of research, including work by Parker and colleagues.

8. Comparing Isordil with Similar Anti-Anginal Agents

Patients and clinicians often compare Isordil with other nitrates and antianginal classes.

• vs. Nitroglycerin (NTG): Sublingual NTG has a faster onset (1-3 min) and shorter duration than sublingual Isordil. Isordil’s metabolites provide a longer duration, making its oral forms more suitable for chronic prophylaxis than oral NTG.
• vs. Isosorbide-5-Mononitrate (ISMN): ISMN is the active metabolite of Isordil. It has 100% bioavailability and is not subject to first-pass metabolism. It is typically dosed once daily due to its longer half-life, which naturally provides a nitrate-free interval, simplifying the tolerance-avoidance regimen.
• vs. Beta-Blockers/Calcium Channel Blockers: These are first-line for chronic prophylaxis. They work via different mechanisms of action (reducing heart rate/contractility or coronary vasodilation). Isordil is often used as add-on therapy when monotherapy is insufficient, or as first-line in patients with contraindications to other agents (e.g., asthma with beta-blockers).

Choosing a Quality Product: For generic isosorbide dinitrate, ensure it is sourced from a reputable manufacturer with FDA approval. Brand-name Isordil may be specified if consistency in formulation is a paramount concern.

9. Frequently Asked Questions (FAQ) about Isordil

What is the most important safety rule when taking Isordil?

Never take Isordil with erectile dysfunction drugs like Viagra (sildenafil), Cialis (tadalafil), or Levitra (vardenafil). This combination can cause a dangerous drop in blood pressure.

How do I prevent Isordil from “stopping working” (tolerance)?

For extended-release tablets, strictly follow the dosing schedule that includes a daily “nitrate-free” period of 10-14 hours, usually overnight. This is critical for maintaining long-term effectiveness.

Can I take Isordil if I have low blood pressure?

It depends on the severity and cause. Isordil lowers blood pressure. If you have chronic low BP or experience dizziness/lightheadedness, your doctor needs to evaluate the risks and benefits and may need to adjust other medications.

What are the most common side effects of Isordil?

Headache (often resolves with continued use), dizziness, lightheadedness, and flushing due to vasodilation. Hypotension and reflex tachycardia can also occur.

How should I store sublingual Isordil tablets?

Keep them in their original glass container, tightly closed, away from light, heat, and moisture. Do not transfer to plastic pill boxes. Replace them every 3-6 months as potency diminishes once opened.

10. Conclusion: Validity of Isordil Use in Clinical Practice

Isordil remains a valid, evidence-based therapeutic option in modern cardiology. Its role is well-defined: as a rapid-acting rescue agent for acute angina and as a prophylactic component, often in combination, for chronic stable angina and specific heart failure populations. The key to its successful long-term use is a disciplined dosing schedule that incorporates a nitrate-free interval to avoid tolerance. When used appropriately with careful attention to its contraindications—most critically the avoidance of concomitant PDE-5 inhibitors—Isordil provides significant symptomatic relief and functional improvement for patients with ischemic heart disease, backed by a substantial body of clinical research.

Clinical Anecdote & Observations

You know, we take these old drugs for granted sometimes. We had a team meeting a while back about updating our CHF protocols, and when I brought up the isosorbide dinitrate/hydralazine combo for our appropriate Black patients, one of the younger hospitalists just shrugged and said, “Isn’t that kind of archaic? We have ARNIs now.” And that’s true, we do, but it sparked a good debate. It forced me to go back and re-read A-HeFT, not just the abstract, but the patient profiles. The thing we forget in the rush to the newest biologic or agent is that this combo has a mortality benefit that’s just as real today as it was in 2004. The struggle is always adherence—twice-daily hydralazine and three-times-daily Isordil is a tough sell.

I remember a specific patient, Mr. Henderson, 68, with Class III HFrEF, EF of 30%. He was on guideline-directed meds but still getting winded walking to his mailbox. He’s African American. We had the conversation about adding the fixed-dose combo of isosorbide dinitrate and hydralazine. He was skeptical—more pills, potential headaches. We started low. The first week, he called about the pounding headache. I told him to hang in there, use some acetaminophen, that it often fades. And it did. At his 3-month follow-up, it was a different story. His wife chimed in on the telehealth call, unsolicited: “He’s out there gardening again. Not all day, but for an hour. He hasn’t done that in two years.” His diuretic requirement actually went down. We bumped his dose to the target. The real test was his 6-minute walk test—he improved his distance by 80 meters. That’s not just a number on a page; that’s him getting back to his roses.

The unexpected finding, something you don’t see in the trial data as clearly, is the psychological shift. When patients with chronic angina get that reliable abortive with sublingual Isordil, the fear of pain diminishes. They feel in control. I saw this with a 52-year-old woman, Linda, who had microvascular angina. Beta-blockers made her too fatigued. We used scheduled extended-release Isordil with a strict 14-hour off period. She kept a log. The data was messy—some days great, some days not—but the trend was fewer episodes. She told me, “Knowing I have the little white pill in my purse if I need it lets me actually go to the grocery store without having a panic attack.” That’s quality of life. That’s valid.

The development struggle, if you will, is internal: fighting the bias that old means obsolete. It doesn’t. It means well-characterized. We know its wrinkles—the tolerance, the headaches, the interactions. We can manage those. The longitudinal follow-up on these patients, the ones we get on the right regimen, shows you that this “archaic” therapy can be profoundly life-altering. It’s a tool. And in the right patient’s hand, it’s still a very sharp one.